These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 22439808)

  • 1. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery.
    Battaglia L; Gallarate M
    Expert Opin Drug Deliv; 2012 May; 9(5):497-508. PubMed ID: 22439808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
    Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
    Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid nanoparticles: promising therapeutic nanocarriers for drug delivery.
    Thukral DK; Dumoga S; Mishra AK
    Curr Drug Deliv; 2014; 11(6):771-91. PubMed ID: 25469779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
    Cheng X; Lee RJ
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
    Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
    Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanostructured lipid carriers (NLCs) for drug delivery and targeting.
    Fang CL; Al-Suwayeh SA; Fang JY
    Recent Pat Nanotechnol; 2013 Jan; 7(1):41-55. PubMed ID: 22946628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment.
    Oliveira MS; Goulart GCA; Ferreira LAM; Carneiro G
    Expert Opin Drug Deliv; 2017 Aug; 14(8):983-995. PubMed ID: 27892713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art.
    Weber S; Zimmer A; Pardeike J
    Eur J Pharm Biopharm; 2014 Jan; 86(1):7-22. PubMed ID: 24007657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics.
    Pathak K; Keshri L; Shah M
    Crit Rev Ther Drug Carrier Syst; 2011; 28(4):357-93. PubMed ID: 21967401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanostructured lipid carriers for site-specific drug delivery.
    Khosa A; Reddi S; Saha RN
    Biomed Pharmacother; 2018 Jul; 103():598-613. PubMed ID: 29677547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
    Banerjee S; Pillai J
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
    [No Abstract]   [Full Text] [Related]  

  • 13. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.
    Harde H; Das M; Jain S
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1407-24. PubMed ID: 21831007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLN, NLC, LDC: state of the art in drug and active delivery.
    Attama AA
    Recent Pat Drug Deliv Formul; 2011 Sep; 5(3):178-87. PubMed ID: 21834777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
    Song A; Zhang X; Li Y; Mao X; Han F
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-based nanoformulations for peptide delivery.
    Matougui N; Boge L; Groo AC; Umerska A; Ringstad L; Bysell H; Saulnier P
    Int J Pharm; 2016 Apr; 502(1-2):80-97. PubMed ID: 26899976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
    Zhang J; Haas RM; Leone AM
    Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release.
    Gordillo-Galeano A; Mora-Huertas CE
    Eur J Pharm Biopharm; 2018 Dec; 133():285-308. PubMed ID: 30463794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. II. Evaluation of the imidazole antifungal drug-loaded nanoparticle dispersions and their gel formulations.
    Das S; Ng WK; Tan RB
    Nanotechnology; 2014 Mar; 25(10):105102. PubMed ID: 24531828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
    Karim R; Palazzo C; Evrard B; Piel G
    J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.